3o9j: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Influenza NA in complex with compound 5== | ==Influenza NA in complex with compound 5== | ||
<StructureSection load='3o9j' size='340' side='right' caption='[[3o9j]], [[Resolution|resolution]] 2.00Å' scene=''> | <StructureSection load='3o9j' size='340' side='right' caption='[[3o9j]], [[Resolution|resolution]] 2.00Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[3o9j]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[3o9j]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/I63a3 I63a3]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3O9J OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3O9J FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=NDG:2-(ACETYLAMINO)-2-DEOXY-A-D-GLUCOPYRANOSE'>NDG</scene>, <scene name='pdbligand=RP6:5-(ACETYLAMINO)-2,6-ANHYDRO-3,5-DIDEOXY-3-PROP-2-EN-1-YL-D-GLYCERO-D-GALACTO-NON-2-ENONIC+ACID'>RP6</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=NDG:2-(ACETYLAMINO)-2-DEOXY-A-D-GLUCOPYRANOSE'>NDG</scene>, <scene name='pdbligand=RP6:5-(ACETYLAMINO)-2,6-ANHYDRO-3,5-DIDEOXY-3-PROP-2-EN-1-YL-D-GLYCERO-D-GALACTO-NON-2-ENONIC+ACID'>RP6</scene></td></tr> | ||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Exo-alpha-sialidase Exo-alpha-sialidase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.2.1.18 3.2.1.18] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Exo-alpha-sialidase Exo-alpha-sialidase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.2.1.18 3.2.1.18] </span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3o9j FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3o9j OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3o9j RCSB], [http://www.ebi.ac.uk/pdbsum/3o9j PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3o9j FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3o9j OCA], [http://pdbe.org/3o9j PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3o9j RCSB], [http://www.ebi.ac.uk/pdbsum/3o9j PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3o9j ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
| Line 17: | Line 18: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 3o9j" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
| Line 25: | Line 27: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Exo-alpha-sialidase]] | [[Category: Exo-alpha-sialidase]] | ||
[[Category: | [[Category: I63a3]] | ||
[[Category: Kerry, P S]] | [[Category: Kerry, P S]] | ||
[[Category: Russell, R J]] | [[Category: Russell, R J]] | ||
[[Category: Hydrolase]] | [[Category: Hydrolase]] | ||
[[Category: Neuraminidase]] | [[Category: Neuraminidase]] | ||
Revision as of 23:10, 4 August 2016
Influenza NA in complex with compound 5Influenza NA in complex with compound 5
Structural highlights
Function[NRAM_I63A3] Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication. Publication Abstract from PubMedInfluenza virus sialidase has an essential role in the virus' life cycle. Two distinct groups of influenza A virus sialidases have been established, that differ in the flexibility of the '150-loop', providing a more open active site in the apo form of the group-1 compared to group-2 enzymes. In this study we show, through a multidisciplinary approach, that novel sialic acid-based derivatives can exploit this structural difference and selectively inhibit the activity of group-1 sialidases. We also demonstrate that group-1 sialidases from drug-resistant mutant influenza viruses are sensitive to these designed compounds. Moreover, we have determined, by protein X-ray crystallography, that these inhibitors lock open the group-1 sialidase flexible 150-loop, in agreement with our molecular modelling prediction. This is the first direct proof that compounds may be developed to selectively target the pandemic A/H1N1, avian A/H5N1 and other group-1 sialidase-containing viruses, based on an open 150-loop conformation of the enzyme. Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase.,Rudrawar S, Dyason JC, Rameix-Welti MA, Rose FJ, Kerry PS, Russell RJ, van der Werf S, Thomson RJ, Naffakh N, von Itzstein M Nat Commun. 2010 Nov;1(8):113. Epub 2010 Nov 16. PMID:21081911[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||